利培酮(Risperidone) - 药物靶点：5-HT2A receptor x D2 receptor_在研适应症：躁郁症1型，自闭症，攻击_专利_临床

概要

基本信息

简介利培酮（商品名为：RISPERDAL®）是一种非典型抗精神病药物。该药品由强生公司开发，于1993年12月29日获得美国食品药品监督管理局（FDA）批准。利培酮用于治疗精神分裂症，以及与双相I型障碍相关的急性躁狂或混合发作，可作为单药治疗或与锂或丙戊酸辅助治疗。此外，该药品还被批准用于治疗与自闭症谱系障碍相关的烦躁情绪。该药品通过抑制多巴胺2型（D2）和5-羟色胺2型（5HT2）受体结合起作用，这被认为是其治疗精神分裂症的疗效贡献之一。利培酮一般耐受性较好，但可能会引起体重增加、嗜睡和锥体外系症状等副作用。

药物类型

小分子化药

别名

Risperdal OD、Risperidone (JP17/USP/INN)、Risperidone for Depot Suspension

+ [45]

靶点

5-HT2A receptor x D2 receptor

作用方式

拮抗剂

作用机制

5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor拮抗剂(多巴胺D2受体拮抗剂)

治疗领域

神经系统疾病其他疾病

在研适应症

躁郁症1型自闭症攻击+ [7]

非在研适应症

急性精神分裂症阿斯伯格综合症注意缺陷和破坏性行为障碍+ [26]

原研机构

Johnson & Johnson

在研机构

Myung in Pharm Co., Ltd.

广州帝奇医药技术有限公司

Laboratorios Farmaceúticos Rovi SA

+ [8]

非在研机构

Janssen Pharmaceutica NVJanssen-Cilag International NV

Janssen Cilag SpA

+ [12]

权益机构

Laboratorios Farmaceúticos Rovi SA

Teva Pharmaceutical Industries Ltd.

友华生技医药股份有限公司

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (1993-12-29),

精神分裂症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C23H27FN4O2

InChIKeyRAPZEAPATHNIPO-UHFFFAOYSA-N

CAS号106266-06-2

关联

534

项与利培酮相关的临床试验

NCT06969755

/ Not yet recruiting临床4期IIT

Biomarkers to Enhance Early Schizophrenia Treatment

This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.

开始日期2025-07-30

申办/合作机构

Northwell Health, Inc.

[+1]

NCT07060872

/ Not yet recruitingN/AIIT

A Randomized Controlled Interventional Study on the Effects of Spirulina Supplementation on Anxiety in Children With Non-Idiopathic Autism

The aim of this study is to evaluate the effect of a Spirulina syrup formulation on reducing anxiety in children with non-idiopathic autism. Participants are referred to a private clinic and assessed by a pediatric neurology subspecialist to confirm the diagnosis. Informed consent is obtained from the parents. Patients are randomly assigned to two groups. The intervention group receives standard treatment (Risperidone tablets) plus Spirulina syrup, while the control group receives Risperidone plus a placebo. Anxiety is measured using the parent version of the Spence Children's Anxiety Scale (SCAS), which includes 38 items rated on a 4-point Likert scale. The questionnaire is administered online via the Porsline platform, and links are sent nightly via social media starting before treatment and continuing daily for one week after treatment initiation, then regularly over a 3-month follow-up period. Data will be analyzed using SPSS version 16. The SCAS consists of six subscales: separation anxiety, social anxiety, phobia, generalized anxiety, panic, and obsessive-compulsive symptoms.

开始日期2025-07-07

申办/合作机构

Shahid Sadoughi University of Medical Sciences and Health Services

NCT06512220

/ Recruiting临床2期IIT

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

Limit: 5000 characters. Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. In healthy volunteers, the psychedelic effects of psilocybin have been shown to be blocked by administration of certain medications such as risperidone.
The purpose of this study is to use an established SV2A radiotracer produced at our Centre to determine the feasibility of integrating PET imaging in to psilocybin trials. The preliminary imaging data will assess whether psilocybin's antidepressant effects are related to changes in synaptic density in adults with TRD, and whether any changes in synaptic density are associated with psilocybin's actions on the 5-HT2AR.

开始日期2025-04-21

申办/合作机构

Centre for Addiction & Mental Health

100 项与利培酮相关的临床结果

登录后查看更多信息

100 项与利培酮相关的转化医学

登录后查看更多信息

100 项与利培酮相关的专利（医药）

登录后查看更多信息

13,533

项与利培酮相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Healthcare resource utilization patterns among patients with Parkinson’s disease psychosis and dementia: analysis of US Medicare beneficiaries treated with pimavanserin versus other-atypical antipsychotics or versus quetiapine

Article

作者: Chrones, Lambros ; Gopal, Daksha ; Doshi, Dilesh ; Rajagopalan, Krithika ; Rashid, Nazia

BACKGROUND:

Pimavanserin (PIM) is the only FDA approved atypical antipsychotic treatment (AAP) for hallucinations and delusions associated with Parkinson's disease psychosis (PDP) among patients with or without coexisting dementia; however, Other-AAPs (i.e. quetiapine (QUE), risperidone, olanzapine, aripiprazole) are commonly prescribed off-label. Healthcare resource utilization (HCRU) patterns among patients with PDP and coexisting dementia (PDP+D) who newly initiate PIM versus (vs.) Other-AAPs (i.e. other AAP-mix) or QUE in real-world settings is limited.

METHODS:

A retrospective analysis of Parts A, B, and D claims from the 100% Medicare sample from 04/01/15 to 12/31/21 was conducted. AAP-naïve patients with PDP+D who initiated ≥12-month continuous monotherapy with PIM vs. Other-AAPs or vs. QUE during 04/01/16-12/31/20 were propensity score matched 1:1 on thirty-one variables (age, sex, race, region and 27 Elixhauser comorbidity characteristics). Adjusted log binomial regressions compared all-cause HCRU [(e.g. inpatient hospitalizations and by hospitalization-type [short-term stays (ST-stays), long-term stays (LT-stays), skilled nursing facility stays (SNF-stays)], and emergency room (ER) visits] risk between cohorts.

RESULTS:

Of the 5,932 patients with PDP+D, matched cohorts (n = 1,294 in each) on continuous- monotherapy of PIM vs. Other-AAPs or QUE had similar demographics and comorbidities. Adjusted regression results showed those who initiated PIM vs. Other-AAPs had significantly lower relative risk (RR) of ≥1 all-cause inpatient hospitalizations (RR = 0.88, 95% CI: 0.80-0.97), ST-stays (RR = 0.86, 95% CI: 0.77-0.95), SNF-stays (RR = 0.79, 95% CI: 0.68-0.92), and ER visits (RR = 0.89, 95% CI: 0.84-0.94). PIM vs. QUE also experienced significantly lower RR for ≥1 all-cause IP hospitalizations (RR = 0.88, 95% CI: 0.80-0.96), ST-stays (RR = 0.85, 95% CI: 0.77-0.95), SNF-stays (RR = 0.81, 95% CI: 0.70-0.94), and ER visits (RR = 0.88, 95% CI: 0.83-0.94).

CONCLUSIONS:

Patients initiating PIM-monotherapy for PDP+D experienced 12% lower all-cause inpatient hospitalizations vs. Other-AAPs or QUE. These results are consistent with prior real-world research in PDP with or without dementia.

2025-12-31·Gut Microbes

Reutericyclin, a specialized metabolite of Limosilactobacillus reuteri , mitigates risperidone-induced weight gain in mice

Article

作者: Kindel, Tammy L ; Smith, Brian C ; Grobe, Justin L ; Hadiono, Matthew A ; Kazen, Alexis B ; Keyes, Robert F ; Aboulalazm, Fatima A ; Kellogg, Stephanie L ; Lozada-Fernandez, Valery ; deLeon, Orlando ; Saravia, Fatima L ; Kirby, John R ; Müller, Susanne

The role of xenobiotic disruption of microbiota, corresponding dysbiosis, and potential links to host metabolic diseases are of critical importance. In this study, we used a widely prescribed antipsychotic drug, risperidone, known to influence weight gain in humans, to induce weight gain in C57BL/6J female mice. We hypothesized that microbes essential for maintaining gut homeostasis and energy balance would be depleted following treatment with risperidone, leading to enhanced weight gain relative to controls. Thus, we performed metagenomic analyses on stool samples to identify microbes that were excluded in risperidone-treated animals but remained present in controls. We identified multiple taxa including Limosilactobacillus reuteri as a candidate for further study. Oral supplementation with L. reuteri protected against risperidone-induced weight gain (RIWG) and was dependent on cellular production of a specialized metabolite, reutericyclin. Further, synthetic reutericyclin was sufficient to mitigate RIWG. Both synthetic reutericyclin and L. reuteri restored energy balance in the presence of risperidone to mitigate excess weight gain and induce shifts in the microbiome associated with leanness. In total, our results identify reutericyclin production by L. reuteri as a potential probiotic to restore energy balance induced by risperidone and to promote leanness.

2025-10-01·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Harnessing integrated bioinformatics to identify new diagnostic and therapeutic strategies for heart failure

Article

作者: Wang, Ruilin ; Shang, Min ; Sun, Shuo ; Fu, Guosheng ; Huang, Chengchen ; Lai, Chaojie

Heart failure (HF) is a life-threatening condition that poses a significant challenge on public health, particularly among the elder populations. To develop new diagnostic and therapeutic strategies for HF, we analyzed large-scale transcriptome sequencing data from HF patients as an exploratory approach. We identified 18 HF-related genes and developed a robust scoring model for HF diagnosis, by applying two machine learning algorithms for data analysis. Meanwhile, we evaluated and compared the predictive abilities of three bioinformatics methods in identifying potential HF treatment drugs. Significantly, an unconventional network-based proximity analysis, integrating multidimensional drug target information, outperformed other methods in the assessment of predictive ability. To validate these findings, we tested several candidate drugs in a mouse model transitioning from acute myocardial infarction (MI) to chronic HF. Among the candidates, mirtazapine exhibited cardioprotective effects in both early (1-week) post-MI and chronic HF (4-week post-MI) settings, while cabergoline showed potential efficacy primarily in the early post-MI phase. Additionally, the screened triamterene, used as a positive control, exhibited protective effects in both early post-MI and chronic HF stages. Mechanistic studies revealed that growth factor receptor-bound protein 14 and Ras-related protein Rab-3A were critical to the observed cardioprotection. These findings provide valuable evidence and insights for exploring potential therapeutic agents for HF treatment.

512

项与利培酮相关的新闻（医药）

2025-09-05

·米内网

【瞩目】齐鲁制药1类新药来袭！抢攻630亿市场

精彩内容近日，CDE官网显示，齐鲁制药申报的化药1类新药QLS1410片获得临床试验默示许可，拟用于治疗未受控制的高血压。米内网数据显示，2024年中国三大终端六大市场（统计范围详见本文末）高血压化药销售额超过630亿元。今年以来，齐鲁制药有1款改良型新药首次获批上市，6款1类新药首次获批临床等。 QLS1410片是齐鲁制药开发的一款化药1类新药，其临床申请于今年7月29日获得CDE承办受理，并于9月2日顺利获批临床，拟用于治疗未受控制的高血压。9月4日，药物临床试验登记与信息公示平台数据显示，该药已启动I期临床，临床试验登记号为CTR20253578，进展堪称神速。米内网数据显示，2024年中国三大终端六大市场高血压化药销售额超过630亿元，2025年一季度超过160亿元，同比略有增长。从细分终端销售看，公立医院（城市公立医院+县级公立医院）为“主战场”，占比超过50%。近年来中国三大终端六大市场高血压化药销售情况（单位：万元）来源：米内网格局数据库从治疗小类看，高血压化药以钙通道阻滞剂（以地平类药物为代表）为主，但其市场份额呈逐年递减态势；高血压复方制剂排位第二，2025年一季度市场份额已增长至超27%；作用于肾素-血管紧张素系统的药物（以沙坦类药物为代表）排位第三。在高血压领域，齐鲁制药拥有9个品种的生产批文，其中盐酸艾司洛尔注射液、卡维地洛片2024年在中国三大终端六大市场的销售额分别超过9亿元、1亿元。QLS1410片是公司首款申报IND且获批进入临床阶段的高血压1类新药。今年以来，齐鲁制药有1款2.2类改良型新药获批上市，为利培酮口腔溶解薄膜。此前，公司已有奥氮平口溶膜、孟鲁司特钠口溶膜、他达拉非口溶膜、阿立哌唑口溶膜、盐酸美金刚口溶膜等多款口溶膜产品获批上市，领跑国内其他企业。齐鲁制药获批上市的口溶膜产品来源：米内网中国上市药品（MID）数据库此外，12款1类新药在国内获批临床，集中在抗肿瘤、自身免疫两大治疗领域，其中QLS1304片、QLS12010胶囊、QLS1209片、注射用QLS5132、注射用QLS5133、QLS1410片均为首次获批临床，且目前均已启动临床。今年以来齐鲁制药获批临床的1类新药注：标*为首次获批来源：米内网中国申报进度（MED）数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至9月5日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

2025-09-03

·ETPharma

FDA clears Lupin bipolar disorder therapy Risperidone with 180-day exclusivity

Mumbai: Drugmaker Lupin announced that its long-acting complex generic for bipolar disorder Risperidone has secured US FDA approval with a 180-day market exclusivity right. While the company markets several complex generics such as Filgrastim, Pegfilgrastim, Etanercept and Albuterol, Risperidone is Lupin’s first product developed using its proprietary tool Nanomi. Nanomi’s LAI platform has demonstrated efficacy and safety in drug delivery. Developed by Nanomi B.V, a subsidiary of Lupin, the toll is used to engineer a drug (LAI) delivery profile to deliver extended-release profiles from weeks to months, superior injectability with smaller needles, and consistent drug concentrations. According to Lupin, the technology can provide lifecycle extension opportunities for products in development or on the market that would benefit from longer-acting formulations. “This first-cycle approval is a testament to the capabilities we have established for complex injectables across our teams in R&D and as we execute on our strategy to evolve specialty/novel products, we plan to leverage the Nanomi platform for novel long-acting injectables that meet unmet patient needs,” said Vinita Gupta , CEO of Lupin. Besides the regulatory approval, the Mumbai-based drugmaker has also unlocked 180 CGT-exclusivity, a clause brought by the FDA to incentivise complex generics where market competition is limited. Notably, according to a FDA guidance document a competitive-generic therapy (CG) market exclusivity is granted even when an innovator's patent is active with the rationale that, “intent to facilitate the efficient development and the timely market entry of drugs for which there is inadequate generic competition.” Lupin’s Risperidone is bioequivalent to the reference listed drug (RLD), Risperdal Consta marketed by pharma giant Johnson and Johnson subsidiary Janssen, L.P. As per IQVIA estimates, as of July this year, Risperdal Consta has a moving annual turnover of $190 million (~Rs 1600 crore) in the US. By Online Bureau ,

上市批准

2025-08-30

·健识局

两款独家品种被调出，今年医保准入更严了

8月28日，国家医保局发布了一份调整后的2025年通过医保目录形式审查的药品名单。国家医保局表示，形式审查名单公示期间，收到业界反馈意见，因此做出调整。有变动的产品均为申报医保目录的药品，共调进、调出了6款药。形式审查名单并不等于最终进入谈判的名单，每年的形式审查名单都会有细微调整，主要是筛过不符合医保政策下“临床价值”、“药物经济性”等观念的产品。随着医保基金精细化管理，医保目录准入标准每年都在不同的细节方面有着更高要求。此次调入的4款产品，基本都是临床价值更高的品种。其中，湘北威尔曼制药的注射用头孢曲松钠舒巴坦钠抗菌谱更广，且是目前唯一长效复方抗生素；紫程众投的葡萄糖酸钙氯化钠注射液安全性更高；左旋多巴注射液、熊去氧胆酸口服混悬液是罕见病用药。今年国家医保局调出的两款产品，均是独家品种，分别是注射用利培酮微球、注射用双羟萘酸曲普瑞林。经整理分析，健识局发现：未通过国谈的“雷点”主要就是临床价值不够。今年2月，圣兆药物的注射用利培酮微球在中国大陆上市，是国内首仿产品。首仿不是不能进医保。2023年，国内罕见病戈谢病无药可医，国家就新增凯莱天成医药的一款首仿药艾格司他。不过，就以注射用利培酮微球而论，目前医保内有更好的选择。据健识局查询国家药品监督管理局，目前注射用利培酮微球共有5个生产批文，除了圣兆药物，还有绿叶制药。绿叶制药的注射用利培酮缓释微球（Ⅱ）很早就已经获批上市，并已经进入医保多年。绿叶的这款产品对释放技术进行了再升级，技术上显然优于圣兆药物的产品。目前，通过形式审查名单的只留了绿叶的注射用利培酮微球（Ⅱ），进行续约谈判。另一款被拿掉的注射用双羟萘酸曲普瑞林是跨国药企益普生的原研产品，2023年在中国上市，目前主要用于治疗前列腺癌、子宫内膜异位症以及中枢性性早熟。但是该药不是稀缺产品，只是曲普瑞林类药大家族中的一款。市面上同类品种已有注射用醋酸曲普瑞林微球，与益普生的注射用双羟萘酸曲普瑞林差别主要在于给药时间，临床意义改善并不大。并且，益普生的品种与同类产品适应症覆盖相似。此次通过形式审查的名单中，丽珠集团自研的注射用醋酸曲普瑞林微球就申报了前列腺癌、子宫内膜异位症。国家医保局可能是认为：前列腺癌、性早熟等领域，医保内早就有了亮丙瑞林可用。从这两个被拿掉的品种来看，国家医保局对新药产品的准入“口味”没有太大变化，整体都在强调“真创新”临床价值。有数据表明，2020年29种临床价值不高且可替代等就被调出；去年，医保目录还因临床已替代或长期未生产供应理由，调出43种药品。值得注意的是，国家对可能“超适应症”的安全边际监管也在收紧。曲普瑞林具有医疗和消费双重属性。这种药物对中枢性性早熟有抑制效果，对性早熟患者会延缓骨龄生长，又可以延缓有长高需求人群延缓发育，临床中多被与生长激素搭配使用。众所周知，国内家长对孩子“长高”的需求导致了生长激素的滥用。相应的，抑制性早熟的药物也被大量使用。这类药物可能会触及敏感的用药安全边界，也会给医保基金带来风险，监管难度很大。限制这类药物进入医保，是有充分考虑的。撰稿丨苗苗编辑丨江芸贾亭运营丨晨曦插图丨视觉中国声明：健识局原创内容，未经许可请勿转载玛仕度肽上市即脱销，信达200亿的目标就靠它了？老百姓大药房“自救”，谢子龙：今后药店主要提供情绪价值恒瑞淋巴瘤1类新药获批上市

上市批准

100 项与利培酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00426	利培酮	N05AX08	DB00734

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
自闭症	美国	Janssen Pharmaceuticals, Inc.	2006-10-06
情绪易怒	美国	Janssen Pharmaceuticals, Inc.	2006-10-06
躁郁症1型	美国	Janssen Pharmaceuticals, Inc.	2003-12-04
攻击	韩国	Myung in Pharm Co., Ltd.	2003-08-02
阿尔茨海默症	韩国	Myung in Pharm Co., Ltd.	2003-08-02
躁狂	韩国	Myung in Pharm Co., Ltd.	2003-08-02
自残行为	韩国	Myung in Pharm Co., Ltd.	2003-08-02
躁郁症	美国	Janssen Pharmaceuticals, Inc.	2002-03-03
精神分裂症	美国	Janssen Pharmaceuticals, Inc.	1993-12-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性精神分裂症	临床3期	美国	Indivior, Inc.	2014-04-01
自杀意念	临床3期	美国	Janssen Pharmaceuticals, Inc.	2004-06-01
创伤后应激障碍	临床3期	美国	Janssen Pharmaceuticals, Inc.	2004-04-01
广泛性焦虑障碍	临床3期	美国	Janssen Pharmaceuticals, Inc.	2004-02-01
恐慌	临床3期	美国	Janssen Pharmaceuticals, Inc.	2004-02-01
躁郁症2型	临床3期	-	Janssen, Inc.	2004-01-01
儿童行为障碍	临床3期	-	Janssen-Cilag Ltd.	2003-09-01
学习障碍	临床3期	-	Janssen-Cilag Ltd.	2003-09-01
难治性抑郁症	临床3期	-	Janssen LP	2002-10-01
难治性抑郁症	临床3期	-	Johnson & Johnson Pharmaceutical Research & Development LLC	2002-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00539071 (CTgov)	临床4期	分裂情感性障碍 \| 精神分裂症	160	long-acting injectable risperidone (Conventional Dose)	顧夢膚淵鏇繭齋範遞築(鏇網選齋築積鬱簾淵醖) = 願願製鬱膚顧簾鏇壓壓憲淵顧襯艱廠構鹽夢網 (夢蓋鹽壓選廠齋築鏇窪, 1.2) 更多	-	2025-08-06
				long-acting injectable risperidone (High Dose Group)	顧夢膚淵鏇繭齋範遞築(鏇網選齋築積鬱簾淵醖) = 壓鑰獵構齋壓憲鑰壓鬱憲淵顧襯艱廠構鹽夢網 (夢蓋鹽壓選廠齋築鏇窪, 1.3) 更多
NEWS 人工标引	N/A	精神分裂症	-	UZEDY	憲願淵蓋簾鑰醖衊選遞(築蓋糧衊遞觸糧鏇繭窪) = 鑰範簾糧鹽醖願糧願壓淵簾製遞積廠築鏇糧遞 (製築膚鑰積壓醖蓋艱獵 ) 更多	积极	2025-05-31
				Second Generation Oral Antipsychotics (SGOAs)	憲願淵蓋簾鑰醖衊選遞(築蓋糧衊遞觸糧鏇繭窪) = 襯廠簾繭淵蓋鹹壓糧餘淵簾製遞積廠築鏇糧遞 (製築膚鑰積壓醖蓋艱獵 ) 更多
P11-6.001 (AAN2025)	N/A	Tourette 综合征一线	1,684	D2 receptor antagonists (D2RAs)	膚襯膚鬱憲繭鏇艱簾鏇(顧簾鏇範鏇窪積壓醖網) = 鬱範衊壓鑰憲積艱廠遞窪壓獵窪襯鏇簾蓋鹽壓 (蓋繭艱鏇鹽窪獵網餘齋 )	不佳	2025-04-07
NCT04201834 (CTgov)	临床2期	亨廷顿舞蹈病	6	risperidone+BioStamp nPoint device	壓觸衊廠選鏇製獵蓋膚(鹽膚選製窪膚獵顧餘蓋) = 窪鹹鬱醖獵鏇鹽觸醖壓夢網遞鑰齋膚夢鹹築構 (鹹膚鏇獵繭膚簾築齋憲, 憲簾獵選醖積鹹餘觸壓 ~ 簾顧壓構製鬱獵選網遞) 更多	-	2025-03-21
NCT04418466 (DLP-114, CTgov)	临床1/2期	精神分裂症	34	risperidone (DLP-114 Alpha-4 (6-months))	鑰簾範選鹽鏇遞繭鬱夢 = 鑰衊鑰膚願繭壓醖觸艱製鬱夢範願鹹鑰鬱醖遞 (獵餘獵艱顧願鏇廠遞夢, 繭糧餘築廠製築夢廠鑰 ~ 鑰廠淵憲網鑰衊齋鏇蓋) 更多	-	2024-12-27
				risperidone (DLP-114 Alpha-7 (12-months))	鑰簾範選鹽鏇遞繭鬱夢 = 鏇窪膚築窪鏇壓衊鑰製製鬱夢範願鹹鑰鬱醖遞 (獵餘獵艱顧願鏇廠遞夢, 獵遞鹹願觸壓構夢鑰憲 ~ 醖淵鹽糧鬱築憲醖獵鑰) 更多
NCT03323437 (CTgov)	临床4期	精神分裂症	26	Risperidone (Patient)	獵淵構鏇積築齋憲蓋繭(鬱遞壓鏇襯襯簾襯顧壓) = 簾衊膚廠醖糧餘醖餘築糧觸構夢獵構廠憲衊糧 (襯願淵構夢遞網築淵衊, 廠蓋艱範廠憲齋築衊壓 ~ 壓築製鬱範壓簾糧夢壓) 更多	-	2024-05-06
				risperidone (Control)	獵淵構鏇積築齋憲蓋繭(鬱遞壓鏇襯襯簾襯顧壓) = 窪鹹鑰鬱鏇壓簾膚築壓糧觸構夢獵構廠憲衊糧 (襯願淵構夢遞網築淵衊, 襯壓範觸憲築壓衊醖鏇 ~ 網觸衊顧夢獵廠憲繭網) 更多
NCT03160521 (FDA_CDER) 人工标引	临床3期	精神分裂症	390	RISVAN 75 mg	憲襯憲蓋鹽觸齋構壓廠(簾遞艱製範鏇醖廠構壓) = 膚製構餘膚窪衊夢製襯窪窪範醖範鬱選顧夢簾 (鏇艱窪糧鑰遞淵選醖製, 1.51)	积极	2024-03-29
				RISVAN 100 mg	憲襯憲蓋鹽觸齋構壓廠(簾遞艱製範鏇醖廠構壓) = 衊鏇蓋艱獵遞壓鬱壓窪窪窪範醖範鬱選顧夢簾 (鏇艱窪糧鑰遞淵選醖製, 1.54)
NCT04418466 (PRNewswire) 人工标引	临床1/2期	精神分裂症	28	DLP-114	壓繭淵淵鏇鑰齋觸製憲(顧廠齋鹽範觸窪鹽膚製) = No serious adverse events (AEs) attributed to DLP-114 were reported, and DLP-114 was well tolerated for up to 12 months, including the initial placement and follow-up removal procedures 觸壓鏇網網構鑰膚鹽淵 (繭範鬱繭顧淵構構膚築 ) 更多	积极	2023-11-16
NCT03503318 (RISE, Literature) 人工标引	临床3期	精神分裂症	544	TV-46000 once monthlyTV-46000 once monthly	膚膚選選築夢醖積製構(選遞襯鑰選憲積簾觸鏇) = significantly prolonged by 5·0 times with TV-46000 once monthly (hazard ratio, 0·200 [95% CI 0·109–0·367]; p<0·0001) and by 2·7 times with TV-46000 once every 2 months (0·375 [0·227–0·618]; p<0·0001) versus placebo. 窪膚鬱製顧遞餘鏇膚憲 (淵鏇遞鏇鑰簾築餘遞餘 ) 更多	积极	2023-11-01
				TV-46000TV-46000 once every 2 months
Literature 人工标引	N/A	急性精神分裂症	58	注射用利培酮微球（Ⅱ）	艱襯遞壓製築膚襯蓋壓(窪製夢醖網襯簾製憲憲) = 2、4、 6 及 8 周末患者 PANSS 总分减分有效率分别为 37.9%（22/58）、70.7%（41/58）、89.7%（52/58）和 89.7%（52/58）遞積窪蓋獵膚鏇憲鑰鹽 (願壓積繭憲鹹繭淵網鬱 ) 更多	积极	2023-07-07